Literature DB >> 1850954

Coronary thrombosis in a patient with May-Hegglin anomaly.

S McDunn1, W Hartz, C Ts'Ao, D Green.   

Abstract

May-Hegglin anomaly (MHA) is a rare hereditary condition that is characterized by cytoplasmic inclusions in leukocytes and giant platelets. Many patients have some degree of thrombocytopenia. Most individuals with MHA are asymptomatic, but 25-43% of patients previously reported have had a hemorrhagic tendency. The authors describe a patient with MHA who had no history of hemorrhage but who developed complete coronary thrombosis after attempted angioplasty despite an apparent platelet count of 24,000 per mm3. Laboratory investigations revealed a normal bleeding time, normal platelet aggregation, and an increase in the size of approximately two-thirds of the platelets. The calculated platelet mass was near normal, which probably explains the thrombosis despite a decrease in platelet numbers. The authors conclude that in some patients with MHA platelets are functionally active both in vivo and in vitro.

Entities:  

Mesh:

Year:  1991        PMID: 1850954     DOI: 10.1093/ajcp/95.5.715

Source DB:  PubMed          Journal:  Am J Clin Pathol        ISSN: 0002-9173            Impact factor:   2.493


  3 in total

1.  Transient hemiparesis in a 14-year-old boy with MYH9 disorders.

Authors:  Katsumasa Kitamura; Shinji Kunishima; Mayu Tahara; Shigetoshi Ogiwara; Nana Dobata; Tomoyuki Dobata; Akemi Sugihara; Taiji Nakashima; Yasushi Sasaki; Kiyoshi Nagumo; Mitsuru Kubota; Yoshikazu Kinugawa; Masahiro Ieko; Satoru Kumaki
Journal:  Int J Hematol       Date:  2012-07-22       Impact factor: 2.490

2.  Thrombotic events in MYH9 gene-related autosomal macrothrombocytopenias (old May-Hegglin, Sebastian, Fechtner and Epstein syndromes).

Authors:  Antonio Girolami; Girolami Antonio; Silvia Vettore; Vettore Silvia; Emanuela Bonamigo; Bonamigo Emanuela; Fabrizio Fabris; Fabris Fabrizio
Journal:  J Thromb Thrombolysis       Date:  2011-11       Impact factor: 2.300

Review 3.  Pathogenesis and management of inherited thrombocytopenias: rationale for the use of thrombopoietin-receptor agonists.

Authors:  Alessandro Pecci
Journal:  Int J Hematol       Date:  2013-05-01       Impact factor: 2.490

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.